Jupiter Neurosciences, Inc. (NASDAQ: JUNS) entered into a securities purchase agreement to sell 307,692 shares of common stock in a registered direct offering expected to generate approximately $2.0 million in gross proceeds. D. Boral Capital LLC is the exclusive placement agent, and the transaction is expected to close on or about Aug. 24, 2026, subject to customary closing conditions. The shares are being offered under Jupiter's effective Form S-3 shelf registration statement, which the U.S. Securities and Exchange Commission declared effective on April 24, 2026. Jupiter is developing treatments for central nervous system disorders and neuroinflammation; its lead JOTROL program, an enhanced-bioavailability resveratrol formulation, is in a Phase IIa Parkinson's disease trial. The company also commercializes Nugevia and has acquired U.S. rights to ALA-002, a patented psychedelic new chemical entity.